Led by world-class management team, board and scientific research collaborators, LineaGen is leveraging new funding round, Utah Population
Database, and other key resources to advance Utah's proven biomarker discovery platform for commercializing first-in-class molecular diagnostic
SALT LAKE CITY, Dec. 19 /PRNewswire/ -- LineaGen Inc. (http://www.LineaGen.com), a biomarker discovery company created to discover and commercialize significant molecular diagnostic innovations in a variety of key healthcare areas, today announced the company's launch with the close of a $5.8-million funding round led by vSpring Capital and Sanderling Biomedical Ventures. Mesa Verde Venture Partners was the third strategic investment partner in the Series A round.
The capital raised will be used to establish a world-class molecular diagnostic commercialization entity for exploration into the nature, causes and treatment of some of the world's most pressing medical and healthcare challenges.
"The launch of LineaGen is an enormous win for Utah and its life science community," said Utah Governor Jon Huntsman Jr. "This is a classic example of how leaders in Utah's life science industry, investment and higher education research communities are working together to provide global leadership in personalized and predictive medicine, one of the core areas of focus in our Clusters economic development initiative."
LineaGen's initial focus includes groundbreaking diagnostic tools for
the advancement of personalized healthcare by furthering genetic
understanding, diagnosis and targeted treatment of significant disorders
and diseases, including:
-- Multiple sclerosis (MS)
-- Chronic Obstructive Pulmonary Disease (COPD), a chronic lung disease
which encompasses both emphysema and chronic bron
|SOURCE LineaGen Inc.|
Copyright©2007 PR Newswire.
All rights reserved